Literature DB >> 30180837

Effect of dexamethasone intravitreal implant (Ozurdex®) on corneal endothelium in retinal vein occlusion patients : Corneal endothelium after dexamethasone implant injection.

Hatice Ayhan Güler1,2, Nurgül Örnek3, Kemal Örnek4, Nesrin Büyüktortop Gökçınar3, Tevfik Oğurel3, Mehmet Erhan Yumuşak3, Zafer Onaran3.   

Abstract

BACKGROUND: To assess corneal endothelial cell changes after intravitreal dexamethasone (DEX) implant (Ozurdex®) injection in patients with macular edema secondary to retinal vein occlusion (RVO).
METHODS: Twenty-two eyes of 22 patients were assessed prospectively after intravitreal 0.7 mg DEX implant injection. Twenty-two eyes of 22 healthy volunteers served as control group. Corneal endothelial cell parameters including endothelial cell density (ECD), coefficient of variation of cell size (CV), percentage of hexagonality (Hex) and central corneal thickness (CCT) were analyzed before and 1 and 3 months after injection by specular microscopy. The results of the study were compared statistically.
RESULTS: There were 17 (77.3%) patients with branch RVO and 5 (22.7%) patients with central RVO. Mean intraocular pressure (IOP) was 14.73 mmHg before injection, 17.05 mmHg at 1 month and 17.15 mmHg at 3 months after injection. Mean IOP at 1 and 3 months were significantly higher than pre-injection value (p = 0.002 and p = 0.003, respectively). There was a statistically significant reduction in mean ECD at 3 months after injection compared to pre-injection and 1 month (p = 0.013, p = 0.009, respectively) in the injected eyes. Mean ECD showed no significant difference in the uninjected fellow eyes during the follow up (p>0.05). Mean CV and Hex did not reveal a statistically significant difference in injected and uninjected fellow eyes (p > 0.05). No significant change was observed in mean CCT values during the follow up (p = 0.8).
CONCLUSION: Intravitreal dexamethasone implant may cause a transient reduction in corneal endothelial cell density in short term without changing cell morphology.

Entities:  

Keywords:  Corneal endothelium; Dexamethasone implant; Retinal vein occlusion; Specular microscopy

Mesh:

Substances:

Year:  2018        PMID: 30180837      PMCID: PMC6122223          DOI: 10.1186/s12886-018-0905-0

Source DB:  PubMed          Journal:  BMC Ophthalmol        ISSN: 1471-2415            Impact factor:   2.209


  26 in total

Review 1.  The Sustained-Release Dexamethasone Implant: Expanding Indications in Vitreoretinal Disease.

Authors:  K G Kapoor; M G Wagner; A L Wagner
Journal:  Semin Ophthalmol       Date:  2014-03-21       Impact factor: 1.975

2.  In-vitro effects of dexamethasone on cellular proliferation, apoptosis, and Na+-K+-ATPase activity of bovine corneal endothelial cells.

Authors:  Wei-Li Chen; Chung-Tien Lin; Chung-Chen Yao; Yu-Hua Huang; Yu-Bin Chou; Hsiang-Shu Yin; Fung-Rong Hu
Journal:  Ocul Immunol Inflamm       Date:  2006-08       Impact factor: 3.070

3.  Effect of corticosteroids on healing of the corneal endothelium in cats.

Authors:  A Solomon; Y Solberg; M Belkin; N Landshman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-05       Impact factor: 3.117

4.  Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results.

Authors:  Julia A Haller; Francesco Bandello; Rubens Belfort; Mark S Blumenkranz; Mark Gillies; Jeffrey Heier; Anat Loewenstein; Young Hee Yoon; Jenny Jiao; Xiao-Yan Li; Scott M Whitcup; Joanne Li
Journal:  Ophthalmology       Date:  2011-07-20       Impact factor: 12.079

Review 5.  Best practices for treatment of retinal vein occlusion.

Authors:  Paul Hahn; Sharon Fekrat
Journal:  Curr Opin Ophthalmol       Date:  2012-05       Impact factor: 3.761

6.  Dexamethasone enhances oxidative stress-induced cell death in murine neural stem cells.

Authors:  Henricus A M Mutsaers; Roshan Tofighi
Journal:  Neurotox Res       Date:  2012-01-12       Impact factor: 3.911

7.  Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.

Authors:  Julia A Haller; Francesco Bandello; Rubens Belfort; Mark S Blumenkranz; Mark Gillies; Jeffrey Heier; Anat Loewenstein; Young-Hee Yoon; Marie-Louise Jacques; Jenny Jiao; Xiao-Yan Li; Scott M Whitcup
Journal:  Ophthalmology       Date:  2010-04-24       Impact factor: 12.079

8.  Concurrent delivery of dexamethasone and VEGF for localized inflammation control and angiogenesis.

Authors:  Siddhesh D Patil; Fotios Papadmitrakopoulos; Diane J Burgess
Journal:  J Control Release       Date:  2006-10-19       Impact factor: 9.776

9.  Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection.

Authors:  H W Kwak; D J D'Amico
Journal:  Arch Ophthalmol       Date:  1992-02

10.  Acute changes in central corneal thickness according to experimental adjustment of intraocular pressure in normal canine eyes.

Authors:  Young-Woo Park; Man-Bok Jeong; Eui Ri Lee; Yesran Lee; Jae-Sang Ahn; Soo-Hyun Kim; Kangmoon Seo
Journal:  J Vet Med Sci       Date:  2013-07-16       Impact factor: 1.267

View more
  2 in total

Review 1.  In vitro dissolution testing models of ocular implants for posterior segment drug delivery.

Authors:  Muhammad Faris Adrianto; Febri Annuryanti; Clive G Wilson; Ravi Sheshala; Raghu Raj Singh Thakur
Journal:  Drug Deliv Transl Res       Date:  2021-08-11       Impact factor: 5.671

2.  The corneal effects of intravitreal dexamethasone implantation.

Authors:  Alper Halil Bayat; Gamze Karataş; Muhammet Mustafa Kurt; Mustafa Nuri Elçioğlu
Journal:  Ther Adv Ophthalmol       Date:  2020-08-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.